Stockscreener 앱 받기
111.10
1.45%
1.59
시간 외 거래:
111.10
전일 마감가:
$109.51
열려 있는:
$110.3
하루 거래량:
730.87K
Relative Volume:
0.71
시가총액:
$6.21B
수익:
$1.34M
순이익/손실:
$-173.66M
주가수익비율:
-26.85
EPS:
-4.1385
순현금흐름:
$-130.49M
1주 성능:
-4.19%
1개월 성능:
+5.09%
6개월 성능:
+124.17%
1년 성능:
+369.77%
1일 변동 폭
$108.95
$112.72
1주일 범위
$107.36
$117.88
52주 변동 폭
$22.76
$117.88
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
명칭
Dianthus Therapeutics Inc
전화
929-999-4055
주소
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
111.10 | 6.13B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | 개시 | Truist | Buy |
| 2025-07-02 | 개시 | William Blair | Outperform |
| 2024-12-20 | 개시 | TD Cowen | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-26 | 개시 | Robert W. Baird | Outperform |
| 2024-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 개시 | H.C. Wainwright | Buy |
| 2024-02-15 | 개시 | Stifel | Buy |
| 2023-12-26 | 개시 | Jefferies | Buy |
| 2023-11-22 | 개시 | Wedbush | Outperform |
| 2023-10-30 | 개시 | Guggenheim | Buy |
| 2023-09-28 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-08-20 | 재개 | Goldman | Neutral |
| 2021-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 재확인 | B. Riley Securities | Buy |
| 2021-06-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-18 | 개시 | B. Riley Securities | Buy |
| 2021-01-07 | 개시 | Mizuho | Buy |
| 2020-06-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-03-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-03-15 | 개시 | Raymond James | Outperform |
모두보기
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighStill a Buy? - MarketBeat
Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com - Investing.com Australia
Dianthus Therapeutics director Simon Read sells $326,553 in stock - Investing.com
Dianthus (DNTH) Stock: Ends Down by 2.20% at $113.00 at the Close; Market Levels: the Supplied Trading Band Runs From $107.35 to $118.65 at the ClosePre-Earnings Momentum - Vinanet
Handelsbanken Fonder AB Invests $1.49 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics SVP Adam M. Veness Exercises 15,000 Stock Options at $18.17 Each - Kalkine Media
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 114.64 USD - Investing.com
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH) - Stock Titan
Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake - Stock Titan
Dianthus therapeutics director Simon Read sells $304k in stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock By Investing.com - Investing.com Nigeria
Dianthus therapeutics director Simon Read sells $304k in stock - Investing.com
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock - Investing.com
Anne Mcgeorge Sells 7,750 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells 16,167 Shares of Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells $424,313.10 in Stock - MarketBeat
Dianthus Therapeutics Insider Sold Shares Worth $844,822, According to a Recent SEC Filing - marketscreener.com
DNTH insider Adam M. Veness plans Rule 144 sale of 16,167 shares - Stock Titan
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 10, 2026) - Stock Titan
Assenagon Asset Management S.A. Makes New Investment in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Evercore Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $134 - Moomoo
HC Wainwright Issues Optimistic Outlook for DNTH Earnings - MarketBeat
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares By Investing.com - Investing.com Australia
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares - Investing.com
Dianthus Therapeutics(DNTH.US) Officer Sells US$17.95 Million in Common Stock - Moomoo
Marino Garcia Sells 166,000 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock - MarketBeat
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 7, 2026) - stocktitan.net
Dynathera (DNTH) insider schedules 3,833-share stock sale under Rule 144 - Stock Titan
Dnth Holdings (DNTH) plans Rule 144 resale of 126,000 shares via Morgan Stanley - Stock Titan
Dianthus Therapeutics (DNTH): T. Rowe Price reports 12.1% ownership stake - Stock Titan
Dianthus Therapeutics (DNTH): T. Rowe Price reports 7.1% stake in common stock - Stock Titan
Dianthus Therapeutics CEO Marino Garcia reports disposal of 166,000 common shares worth $17.97 million - Bitget
Dianthus Therapeutics (DNTH) Stock Analysis: A Promising Biotech with 19.46% Potential Upside - DirectorsTalk Interviews
The Manufacturers Life Insurance Company Grows Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
DIANTHUS THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $131 FROM $125 - webull.com
DIANTHUS THERAPEUTICS INC : WEDBUSH RAISES TARGET PRICE TO $122 FROM $105 - webull.com
Dianthus Therapeutics Inc (DNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.07%
자본화:
|
볼륨(24시간):